A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
Clinical trial NCT06190951 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06190951
- Sponsor
- Regeneron Pharmaceuticals
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-09-18
- Primary completion
- 2026-11-02
- Enrollment
- 151
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.